12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Opsumit macitentan regulatory update

Actelion submitted an NDA to FDA for Opsumit macitentan to treat pulmonary arterial hypertension. The application is based on data from the Phase III SERAPHIN trial, which showed Opsumit met the primary...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >